Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Evaluation of the Risks and Benefits of CT Urography for Assessment of Gross Hematuria.

Yecies T, Bandari J, Macleod L, Fam M, Davies BJ, Jacobs BL.

Urology. 2019 Jun 27. pii: S0090-4295(19)30596-5. doi: 10.1016/j.urology.2019.04.055. [Epub ahead of print]

PMID:
31255539
2.

A Radical Proposition: Opioid-sparing Prostatectomy.

Theisen KM, Davies BJ.

Eur Urol Focus. 2019 Jun 20. pii: S2405-4569(19)30166-X. doi: 10.1016/j.euf.2019.06.011. [Epub ahead of print]

PMID:
31231009
3.

E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer.

Li F, Pascal LE, Stolz DB, Wang K, Zhou Y, Chen W, Xu Y, Chen Y, Dhir R, Parwani AV, Nelson JB, DeFranco DB, Yoshimura N, Balasubramani GK, Gingrich JR, Maranchie JK, Jacobs BL, Davies BJ, Hrebinko RL, Bigley JD, McBride D, Guo P, He D, Wang Z.

Prostate. 2019 Aug;79(11):1226-1237. doi: 10.1002/pros.23806. Epub 2019 Jun 18.

PMID:
31212363
4.

The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.

Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF.

Eur Urol. 2019 Sep;76(3):268-272. doi: 10.1016/j.eururo.2019.05.013. Epub 2019 May 23.

PMID:
31128968
5.

Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.

Macleod LC, Yabes JG, Yu M, Fam MM, Hale NE, Turner RM 2nd, Lopa SH, Gingrich JR, Borza T, Skolarus TA, Davies BJ, Jacobs BL.

Urol Oncol. 2019 Jul;37(7):462-469. doi: 10.1016/j.urolonc.2019.04.006. Epub 2019 Apr 30.

PMID:
31053530
6.

Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.

Macleod LC, Yabes JG, Fam MM, Bandari J, Yu M, Maganty A, Furlan A, Filson CP, Davies BJ, Jacobs BL.

Eur Urol Focus. 2019 Apr 25. pii: S2405-4569(19)30124-5. doi: 10.1016/j.euf.2019.04.008. [Epub ahead of print]

PMID:
31031042
7.

Downstream Studies Following the Use of Bone Scan in the Staging of Muscle-invasive Bladder Cancer.

Maganty A, Turner RM 2nd, Yabes JG, Davies BJ, Heron DE, Jacobs BL.

Urology. 2019 Jul;129:74-78. doi: 10.1016/j.urology.2019.04.009. Epub 2019 Apr 18.

PMID:
31005656
8.

Increasing Utilization of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.

Fam MM, Yabes JG, Macleod LC, Bandari J, Turner RM 2nd, Lopa SH, Furlan A, Filson CP, Davies BJ, Jacobs BL.

Urology. 2019 Aug;130:99-105. doi: 10.1016/j.urology.2019.02.037. Epub 2019 Mar 30.

PMID:
30940480
9.

Editorial Comment.

Bandari J, Maganty A, Davies BJ.

Urology. 2019 Feb;124:125-126. doi: 10.1016/j.urology.2018.07.056. No abstract available.

PMID:
30784708
10.

Palliative care use amongst patients with bladder cancer.

Hugar LA, Lopa SH, Yabes JG, Yu JA, Turner RM 2nd, Fam MM, MacLeod LC, Davies BJ, Smith AB, Jacobs BL.

BJU Int. 2019 Jun;123(6):968-975. doi: 10.1111/bju.14708. Epub 2019 Mar 12.

PMID:
30758125
11.

Small cell bladder cancer: should we consider prophylactic cranial irradiation?

Morgan TN, Turner RM II, Baptiste J, Lyon TD, Maranchie JK, Hrebinko RL, Davies BJ, Gingrich JR, Jacobs BL.

Int Braz J Urol. 2019 Mar-Apr;45(2):299-305. doi: 10.1590/S1677-5538.IBJU.2018.0242.

12.

The American Opioid Crisis: The Inexorable March to Death and Addiction.

Theisen K, Davies BJ.

Eur Urol. 2019 Feb;75(2):219-220. doi: 10.1016/j.eururo.2018.10.051. Epub 2018 Nov 12. No abstract available.

PMID:
30442426
13.

Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries With Bladder Cancer: A SEER-Medicare Analysis.

Hugar LA, Yabes JG, Turner RM 2nd, Fam MM, Appleman LJ, Davies BJ, Jacobs BL.

Urology. 2019 Feb;124:191-197. doi: 10.1016/j.urology.2018.11.001. Epub 2018 Nov 10.

PMID:
30423302
14.

Concentration of Opioid-Related Industry Payments in Opioid Crisis Areas.

Lee AJ, Bandari J, Macleod LC, Davies BJ, Jacobs BL.

J Gen Intern Med. 2019 Feb;34(2):187-189. doi: 10.1007/s11606-018-4700-7. No abstract available.

PMID:
30402818
15.

Extreme Price Variation for Generic Benign Prostatic Hyperplasia Medications.

Theisen KM, Park SY, Jeong K, Macleod LC, Bandari J, Ayyash O, Odisho AY, Jacobs BL, Davies BJ.

Urology. 2019 Feb;124:223-228. doi: 10.1016/j.urology.2018.10.020. Epub 2018 Oct 23.

PMID:
30359708
16.

Erratum to expanded criteria for active surveillance in prostate cancer: a review of the current data.

Jones C, Fam MM, Davies BJ.

Transl Androl Urol. 2018 Aug;7(4):764. doi: 10.21037/tau.2018.08.05.

17.

Excessive Opioid Prescribing After Major Urologic Procedures.

Theisen KM, Myrga JM, Hale N, Cochran G, Sewall C, Macleod LC, Jacobs BL, Davies BJ.

Urology. 2019 Jan;123:101-107. doi: 10.1016/j.urology.2018.06.057. Epub 2018 Aug 24.

PMID:
30149041
18.

Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Guérin.

Bandari J, Maganty A, MacLeod LC, Davies BJ.

Eur Urol Focus. 2018 Jul;4(4):481-484. doi: 10.1016/j.euf.2018.06.018. Epub 2018 Jul 11. Review.

PMID:
30005997
19.

Effect of multimodal analgesia with paravertebral blocks on biochemical recurrence in men undergoing open radical prostatectomy.

Macleod LC, Turner RM 2nd, Lopa S, Hugar LA, Davies BJ, Ben-David B, Chelly JE, Jacobs BL, Nelson JB.

Urol Oncol. 2018 Aug;36(8):364.e9-364.e14. doi: 10.1016/j.urolonc.2018.05.016. Epub 2018 Jun 7.

PMID:
29887239
20.

Expanded criteria for active surveillance in prostate cancer: a review of the current data.

Jones C, Fam MM, Davies BJ.

Transl Androl Urol. 2018 Apr;7(2):221-227. doi: 10.21037/tau.2017.08.23. Review. Erratum in: Transl Androl Urol. 2018 Aug;7(4):764.

21.

Active surveillance for prostate cancer.

Dall'Era MA, Davies BJ, Eggener S.

Transl Androl Urol. 2018 Apr;7(2):195-196. doi: 10.21037/tau.2018.03.03. No abstract available.

22.

The comparative effectiveness of quadratus lumborum blocks and paravertebral blocks in radical cystectomy patients.

Lee AJ, Yabes JG, Hale N, Hrebinko RL, Gingrich JR, Maranchie JK, Fam MM, Turner I I RM, Davies BJ, Ben-David B, Jacobs BL.

Can J Urol. 2018 Apr;25(2):9255-9261..

PMID:
29680003
23.

Evaluation of Vasectomy Trends in the United States.

Ostrowski KA, Holt SK, Haynes B, Davies BJ, Fuchs EF, Walsh TJ.

Urology. 2018 Aug;118:76-79. doi: 10.1016/j.urology.2018.03.016. Epub 2018 Mar 22.

PMID:
29578040
24.

Physician Reimbursement for Prostate Biopsies Falls as Procedures Shift From Offices to Facilities.

Henry MA, Howard DH, Davies BJ, Filson CP.

Urology. 2018 May;115:96-101. doi: 10.1016/j.urology.2018.02.008. Epub 2018 Mar 12.

PMID:
29545049
25.

Marketing and Testosterone Treatment in the USA: A Systematic Review.

Bandari J, Ayyash OM, Emery SL, Wessel CB, Davies BJ.

Eur Urol Focus. 2017 Oct;3(4-5):395-402. doi: 10.1016/j.euf.2017.10.016. Epub 2017 Nov 23. Review.

PMID:
29174614
26.

Evidence-Based Reporting: A Method to Optimize Prostate MRI Communications With Referring Physicians.

Magnetta MJ, Donovan AL, Jacobs BL, Davies BJ, Furlan A.

AJR Am J Roentgenol. 2018 Jan;210(1):108-112. doi: 10.2214/AJR.17.18260. Epub 2017 Nov 1.

PMID:
29091009
27.

The use of intraoperative cell salvage in urologic oncology.

Ferroni MC, Correa AF, Lyon TD, Davies BJ, Ost MC.

Rev Urol. 2017;19(2):89-96.

28.

Preoperative immunonutrition prior to radical cystectomy: a pilot study.

Lyon TD, Turner I I RM, McBride D, Wang L, Gingrich JR, Hrebinko RL, Jacobs BL, Davies BJ, Tarin TV.

Can J Urol. 2017 Aug;24(4):8895-8901.

PMID:
28832307
29.

Chipping away at the body politic one study at a time: the case for more 'unprofessional' online content.

Bayne CE, Davies BJ.

BJU Int. 2017 Nov;120(5):609-610. doi: 10.1111/bju.13986. Epub 2017 Sep 5. No abstract available.

30.

The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.

Bandari J, Ayyash OM, Turner RM 2nd, Jacobs BL, Davies BJ.

Cancer. 2017 Nov 15;123(22):4356-4362. doi: 10.1002/cncr.30914. Epub 2017 Jul 27.

31.

Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines.

Henry MA, Howard DH, Davies BJ, Filson CP.

J Urol. 2017 Nov;198(5):1046-1053. doi: 10.1016/j.juro.2017.05.008. Epub 2017 May 6.

PMID:
28487099
32.

Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer.

Davies BJ, Hwang TJ, Kesselheim AS.

N Engl J Med. 2017 Apr 13;376(15):1401-1403. doi: 10.1056/NEJMp1615697. No abstract available.

PMID:
28402764
33.

Variations in Preoperative Use of Bone Scan Among Medicare Beneficiaries Undergoing Radical Cystectomy.

Turner RM 2nd, Yabes JG, Davies BJ, Heron DE, Jacobs BL.

Urology. 2017 May;103:84-90. doi: 10.1016/j.urology.2017.02.028. Epub 2017 Feb 24.

34.

The Relationship of Industry Payments to Prescribing Behavior: A Study of Degarelix and Denosumab.

Bandari J, Turner RM 2nd, Jacobs BL, Canes D, Moinzadeh A, Davies BJ.

Urol Pract. 2017 Jan;4(1):14-20. doi: 10.1016/j.urpr.2016.03.007.

35.

Biopsy Perineural Invasion in Prostate Cancer Patients Who Are Candidates for Active Surveillance by Strict and Expanded Criteria.

Turner RM 2nd, Yecies TS, Yabes JG, Ristau BT, Woldemichael E, Davies BJ, Jacobs BL, Nelson JB.

Urology. 2017 Apr;102:173-177. doi: 10.1016/j.urology.2016.11.011. Epub 2016 Nov 15.

36.

Urology Payments from Industry in the Sunshine Act.

Bandari J, Turner RM 2nd, Jacobs BL, Davies BJ.

Urol Pract. 2016 Sep;3(5):332-337.

37.

Molecular Cytogenetics as a Diagnostic Aid for Primary Liposarcoma of the Spermatic Cord.

Hugar LA, Quiroga-Garza GM, Davies BJ, Hrebinko RL, Tran T, Jacobs BL.

Clin Genitourin Cancer. 2017 Feb;15(1):e83-e89. doi: 10.1016/j.clgc.2016.08.008. Epub 2016 Aug 10. Review. No abstract available.

PMID:
27666164
38.

Payments to Pediatricians in the Sunshine Act.

Karas DJ, Bandari J, Browning DN, Jacobs BL, Davies BJ.

Clin Pediatr (Phila). 2017 Jul;56(8):723-728. doi: 10.1177/0009922816670981. Epub 2016 Sep 23.

PMID:
27663966
39.

Preoperative Statin Use at the Time of Radical Prostatectomy Is Not Associated With Biochemical Recurrence or Pathologic Upgrading.

Lyon TD, Turner RM 2nd, Yabes JG, Woldemichael E, Davies BJ, Jacobs BL, Nelson JB.

Urology. 2016 Nov;97:153-159. doi: 10.1016/j.urology.2016.08.004. Epub 2016 Aug 8.

PMID:
27516122
40.

Panniculectomy and Cystectomy: An Approach to the Morbidly Obese Patient.

Hugar LA, Turner RM, Gusenoff JA, Correa AF, Jacobs BL, Davies BJ.

Case Rep Urol. 2016;2016:6980843. doi: 10.1155/2016/6980843. Epub 2016 Apr 18.

41.

Partial and hemi-nephrectomy for renal malignancy in patients with horseshoe kidney.

Yecies T, Turner Іi RM, Ferroni MC, Jacobs BL, Davies BJ.

Can J Urol. 2016 Feb;23(1):8156-9.

PMID:
26892057
42.

Total Psoas Area Predicts Complications following Radical Cystectomy.

Lyon TD, Farber NJ, Chen LC, Fuller TW, Davies BJ, Gingrich JR, Hrebinko RL, Maranchie JK, Taylor JM, Tarin TV.

Adv Urol. 2015;2015:901851. doi: 10.1155/2015/901851. Epub 2015 Dec 21.

43.

Effect of a concomitant urologic procedure on outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Lyon TD, Turner Ii RM, Nikonow TN, Wang L, Uy J, Ramalingam L, Holtzman MP, Pingpank JF, Bartlett DL, Davies BJ.

J Surg Oncol. 2016 Feb;113(2):218-22. doi: 10.1002/jso.24115. Epub 2016 Jan 18.

PMID:
26775909
44.

Pioglitazone Use and Risk of Bladder Cancer.

Davies BJ.

JAMA. 2015 Dec 15;314(23):2568. doi: 10.1001/jama.2015.13909. No abstract available.

PMID:
26670977
45.

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer.

Correa AF, Theisen K, Ferroni M, Maranchie JK, Hrebinko R, Davies BJ, Gingrich JR.

Adv Urol. 2015;2015:656918. doi: 10.1155/2015/656918. Epub 2015 Oct 13.

46.

Short-term Outcomes of Intraoperative Cell Saver Transfusion During Open Partial Nephrectomy.

Lyon TD, Ferroni MC, Turner RM 2nd, Jones C, Jacobs BL, Davies BJ.

Urology. 2015 Dec;86(6):1153-8. doi: 10.1016/j.urology.2015.09.008. Epub 2015 Sep 24.

PMID:
26387849
47.

Clinical Case Discussion: Intermediate-risk Prostate Cancer: The Case for Active Surveillance.

Dall'Era MA, Davies BJ.

Eur Urol Focus. 2015 Sep;1(2):208-209. doi: 10.1016/j.euf.2015.07.001. Epub 2015 Jul 15.

PMID:
28723436
48.

Radical versus partial nephrectomy.

Jacobs BL, Davies BJ.

Health Aff (Millwood). 2015 May;34(5):881. doi: 10.1377/hlthaff.2015.0276. No abstract available.

PMID:
25941293
49.

Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research.

Parikh RA, Pascal LE, Davies BJ, Wang Z.

Asian J Androl. 2014 Jul-Aug;16(4):505-10. doi: 10.4103/1008-682X.125410. Review.

50.

International Urology Journal Club via Twitter: 12-month experience.

Thangasamy IA, Leveridge M, Davies BJ, Finelli A, Stork B, Woo HH.

Eur Urol. 2014 Jul;66(1):112-7. doi: 10.1016/j.eururo.2014.01.034. Epub 2014 Feb 7.

PMID:
24548686

Supplemental Content

Loading ...
Support Center